The US drug regulator declined to extend its approval for AstraZeneca’s Fasenra (benralizumab) for the treatment of chronic rhinosinusitis with nasal polyps. Declining the company’s application for extended use, the Food and Drug Administration has asked for more clinical data from the company to extend the use of this biological drug, which was approved for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype in 2017. However, it was  not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.